Overview

Also Known As: TetO-c-Myc, TRE-MYC, tet-o-MYC line 36

These TRE-MYC (TetO-c-Myc or Teto-MYC) hemizygous transgenic mice carry the human myelocytomatosis oncogene, MYC, regulated by a tetracycline operator (tetO). When mated to a mutant strain expressing tetracycline-controlled transactivator protein (tTA), expression of MYC protein may be regulated with tetracycline or its analog doxycycline (dox) in the double mutant offspring.These mice may be useful for studying tumor development and regression.

Donating Investigator

J Michael Bishop, UCSF School of Medicine

Genetic overview

Genetic Background	Generation

Tg(tetO-MYC)36aBop

Allele Type
Transgenic (Inducible, Inserted expressed sequence, Humanized sequence)

View Genetics

Research Applications

Research Tools
Cancer Research

View All Research Applications

Base Price

Starting at:

$2,854.50 Domestic price Cryo Recovery

View Price List

Details

Detailed Description

Expression of MYC in these transgenic mice is regulated by a tetracycline operator (tetO). MYC is a transcription factor involved in cellular proliferation and differentiation, and is often upregulated in tumors, leukemias and lymphomas. Hemizygous mice are viable and fertile, homozygotes do not survive. When mated to a mutant strain expressing tetracycline-controlled transactivator protein (tTA), expression of MYC protein may be regulated with tetracycline or its analog doxycycline (dox) in the double mutant offspring.

When bred to B6.Cg-Tg(Cebpb-tTA)5Bjd/J mice (as Stock No. 003563) expressing tTA in liver, withdrawal of dox from double transgenic mice develop invasive metastatic liver tumors, and all mice die within 2 weeks onset. When doxycycline treatment is re-administered, rapid and sustained tumor regression is evident.

When bred to B6.Cg-Tg(Pax8-rtTA2S*M2)1Koes/J (see Stock No. 007176) expressing rtTA in renal tubular epithelial cells, induction of doxycycline causes polycystic kidneys, kidney failure and renal adenomas.

Development

A transgenic vector was generated encoding the human myelocytomatosis viral oncogene cDNA (MYC) under control of a tetO promoter. The construct was microinjected into FVB/NJ fertilized oocytes, and mice from founder line 36a were bred to FVB/NJ mice for at least 10 generations to establish a colony. Upon arrival at The Jackson Laboratory Repository, mice were bred to FVB/NJ mice (as Stock No. 001800) for at least one generation.

Expression Data

Expressed Gene	MYC, MYC proto-oncogene, bHLH transcription factor, human
Site of Expression

Control Suggestions

Noncarrier

Approximate Controls

001800 FVB/NJ

Additional Information

Considerations for Choosing Controls

Selected References

Felsher DW; Bishop JM. 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4(2):199-207PubMed: 10488335 MGI: J:59444

View All References

Genetics

Tg(tetO-MYC)36aBop

Allele Symbol: Tg(tetO-MYC)36aBop

Allele Name	transgene insertion 36a, J Michael Bishop
Allele Type	Transgenic (Inducible, Inserted expressed sequence, Humanized sequence)
Allele Synonym(s)	Tg(tetO-MYC)36aBop; transgene insertion 36a, J Michael Bishop
Gene Symbol and Name	Tg(tetO-MYC)36aBop, transgene insertion 36a, J Michael Bishop
Gene Synonym(s)
Promoter	tetO, tet operator,
Expressed Gene	MYC, MYC proto-oncogene, bHLH transcription factor, human
Strain of Origin	FVB/N
Chromosome	UN
General Note	Phenotypic Similarity to Human Syndrome: Renal Cell Carcinoma J:222943.
Molecular Note	This transgene contains a human v-myc avian myelocytomatosis viral oncogene homolog cDNA and regulatory elements from the bacterial tetracycline-resistance operon. There are two founder #36 lines. Transgene insertions are on an autosomal chromosome in this line.
Mutations Made By	J Michael Bishop, UCSF School of Medicine

Disease/Phenotype

Disease Terms

Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Research Tools
- Genetics Research
  - Mutagenesis and Transgenesis: Tetop Tet System
- Tet Expression Systems
  - tTA/rtTA Responsive Strains
- Cancer Research
  - Tetop Tet System
Cancer Research
- Increased Tumor Incidence
- Oncogenes
- Other
  - tumor metastasis
- Genes Regulating Growth and Proliferation

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Tg(Pax8-rtTA2SM2)1Koes/0 Tg(tetO-MYC)36aBop/0
involves: C57BL/6 DBA * FVB/N

neoplasm

increased adenoma incidence
- following induction with doxycycline, mice develop renal adenomas

increased renal carcinoma incidence
- following induction with doxycycline

renal/urinary system phenotype

increased renal carcinoma incidence
- following induction with doxycycline

kidney cysts
- following induction with doxycycline, mice develop glomerular cysts

kidney failure
- 3 to 4 months following induction with doxycycline

polycystic kidney
- following induction with doxycycline, mice develop multiple renal cysts in all renal tubular compartments

Genotype: Tg(tetO-MYC)36aBop/0 Tg(Cebpb-tTA)5Bjd/0
involves: FVB/N * NMRI

liver/biliary system phenotype

increased hepatoblastoma incidence
- liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas

increased hepatocellular carcinoma incidence
- Normal - however, treatment with adeno-associated virus-expressing Mir122 suppresses tumorigenesis
- in doxycycline-treated mice
- liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas
- mice develop multifocal hepatocellular carcinoma within 5-8 weeks of age when doxycycline is removed at birth, showing invasive tumor cells in glandular and solid pattern infiltrating adjacent normal liver tissue
- tumors show a range of differentiation between well- and moderately-differentiated hepatocellular carcinoma
- tumors that form in mice after doxycycline withdrawal are composed of hepatocellular neoplasms characterized by sheets of cells with occasional mitotic figure, slightly pleomorphic nuclei, and prominent nucleoli

increased liver tumor incidence
- following withdrawal of doxycycline, mice develop tumors with a latency of 12 weeks and all mice succumb to liver tumors within 2 weeks
- Normal - however, re-establishment of doxycycline-treatment produces rapid and sustained tumor regression
- liver tumors that develop in mice after doxycycline withdrawal are invasive and metastasis into the thoracic cavity and lung parenchyma
- repeated withdrawal and treatment with doxycyclineinduces and represses, respectively, tumor formation

mortality/aging

premature death
- following withdrawal of doxycycline, all mice succumb to liver tumors within 2 weeks
- median survival of mutants is 31 weeks following doxycycline withdrawal to induce MYC expression
- median survival of mutants with tumors is 27 weeks following doxycycline withdrawal to induce MYC expression

neoplasm

decreased tumor growth/size
- doxycycline-treated mice infected with an adeno-associated virus-expressing Mir122 exhibit suppression of tumorigenesis tumor cell proliferation compared with control mice

increased hepatoblastoma incidence
- liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas

increased hepatocellular carcinoma incidence
- Normal - however, treatment with adeno-associated virus-expressing Mir122 suppresses tumorigenesis
- in doxycycline-treated mice
- liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas
- mice develop multifocal hepatocellular carcinoma within 5-8 weeks of age when doxycycline is removed at birth, showing invasive tumor cells in glandular and solid pattern infiltrating adjacent normal liver tissue
- tumors show a range of differentiation between well- and moderately-differentiated hepatocellular carcinoma
- tumors that form in mice after doxycycline withdrawal are composed of hepatocellular neoplasms characterized by sheets of cells with occasional mitotic figure, slightly pleomorphic nuclei, and prominent nucleoli

increased liver tumor incidence
- following withdrawal of doxycycline, mice develop tumors with a latency of 12 weeks and all mice succumb to liver tumors within 2 weeks
- Normal - however, re-establishment of doxycycline-treatment produces rapid and sustained tumor regression
- liver tumors that develop in mice after doxycycline withdrawal are invasive and metastasis into the thoracic cavity and lung parenchyma
- repeated withdrawal and treatment with doxycyclineinduces and represses, respectively, tumor formation

References

Felsher DW; Bishop JM. 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4(2):199-207PubMed: 10488335 MGI: J:59444

Additional - Tg(tetO-MYC)36aBop related

Technical Support

Contact Technical Support

Genotyping Protocols
- Separated PCR:Tg(tetO-MYC)36aBop
- Standard PCR:Tg(tetO-MYC)36aBop
- Genotyping resources and troubleshooting
Breeding Considerations

When maintaining a live colony, hemizygous mice may be bred to wildtype (non-carrier) mice from the colony or to FVB/NJ inbred mice (as Stock No. 001800). Homozygous mice do not survive.
- Additional Breeding and Husbandry Support
Citation
When using the tet-o-MYC line 36 mouse strain in a publication, please cite the originating article(s) and include JAX stock #019376 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Pricing & Availability

Cryo Recovery

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Cryorecovery - Pricing

Service	Genotype	Price
	Hemizygous or Non carrier forTg(tetO-MYC)36aBop

We will fulfill your order by providing at least two carriers for each strain ordered. The total number, sex, and genotypes provided will vary, although typically 8 or more animals are provided. Please check genotypes which will be recovered. While the genotypes of all animals produced will be communicated to you prior to scheduling shipment, the genotypes of animals provided may not reflect the mating scheme and genotypes described in the strain description. Animals are typically ready to ship in 11-14 weeks. If a second recovery is required to produce the minimum number of animals, then delivery time would increase to approximately 25 weeks. If we fail to produce animals of the correct genotype, you will not be charged. We cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation.

Related Products and Services

Frozen Mouse Embryo	FVB/N-Tg(tetO-MYC)36aBop/J	$2595.00
Frozen Mouse Embryo	FVB/N-Tg(tetO-MYC)36aBop/J	$2595.00
Frozen Mouse Embryo	FVB/N-Tg(tetO-MYC)36aBop/J	$3373.50
Frozen Mouse Embryo	FVB/N-Tg(tetO-MYC)36aBop/J	$3373.50

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

Terms Of Use

Terms of Use

General Terms and Conditions

Questions about Terms of Use

Additional Use Restrictions Apply

Notice to customers in Canada.

Use of MICE by companies or for-profit entities requires a license prior to shipping.

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As: TetO-c-Myc, TRE-MYC, tet-o-MYC line 36

Donating Investigator

Genetic overview

Research Applications

Base Price

Detailed Description

Development

Expression Data

Control Suggestions

Approximate Controls

Additional Information

Selected References

Tg(tetO-MYC)36aBop

Allele Symbol: Tg(tetO-MYC)36aBop

Disease Terms

Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Mammalian Phenotype Terms by Genotype

Genotype: Tg(Pax8-rtTA2S*M2)1Koes/0 Tg(tetO-MYC)36aBop/0involves: C57BL/6 * DBA * FVB/N

neoplasm

renal/urinary system phenotype

Genotype: Tg(tetO-MYC)36aBop/0 Tg(Cebpb-tTA)5Bjd/0involves: FVB/N * NMRI

liver/biliary system phenotype

mortality/aging

neoplasm

References

Additional - Tg(tetO-MYC)36aBop related

Genotyping Protocols

Breeding Considerations

Citation

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Live Mouse

Cryorecovery - Pricing

Related Products and Services

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms of Use

Additional Use Restrictions Apply

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Genotype: Tg(Pax8-rtTA2SM2)1Koes/0 Tg(tetO-MYC)36aBop/0
involves: C57BL/6 DBA * FVB/N

Genotype: Tg(tetO-MYC)36aBop/0 Tg(Cebpb-tTA)5Bjd/0
involves: FVB/N * NMRI